{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:18:35Z","timestamp":1783466315427,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Frederik Meijer Heart and Vascular Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2002<\/jats:title>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>The Magna Ease aortic valve (Edwards Lifesciences, Irvine, CA) is a third-generation bioprosthetic valve developed as a modification of the well-studied Perimount and Magna valve designs. This study\u2019s objective is to evaluate a large, single-centre experience with Magna Ease aortic valve replacement (AVR) focusing on clinical outcomes and haemodynamic performance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>All patients undergoing AVR between 8\/2010 and 10\/2018 at our institution implanted with the Magna Ease valve were included except those undergoing ventricular assist device or congenital aortic surgery. Primary outcomes were overall survival and freedom from reoperation. Mean transprosthetic gradient (mTPG) and structural valve deterioration (SVD) served as secondary outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Totally 1126 consecutive implantations of Magna Ease valves were included. Concomitant procedures were performed in 56.5% (n\u2009=\u2009636). No severe patient\u2013prosthesis mismatch (PPM) was present at implantation. Overall survival at 30\u2009days, 1\u2009year, 5\u2009years and 9\u2009years was 97.2%, 95.0%, 86.1% and 78.2%, respectively, with improved survival for isolated AVR. Total of 2.4% (n\u2009=\u200927) of patients required reoperation with 0.3% (n\u2009=\u20094) for SVD. Echocardiographic follow-up data revealed low mTPG throughout the study period. SVD occurred in 28.7% of patients at a mean of 3.9\u2009years post implantation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Magna Ease AVR maintained low mean transprosthetic gradients throughout mid-term evaluation and was associated with excellent overall survival and freedom from reoperation at nine years post implantation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/icvts\/ivab016","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T23:56:59Z","timestamp":1610582219000},"page":"839-845","source":"Crossref","is-referenced-by-count":18,"title":["Magna ease bioprosthetic aortic valve: mid-term\u00a0haemodynamic outcomes in 1126 patients"],"prefix":"10.1093","volume":"32","author":[{"given":"Stephen D","family":"Thorp","sequence":"first","affiliation":[{"name":"General Surgery Residency, Spectrum Health\/Michigan State University, Grand Rapids, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9948-1232","authenticated-orcid":false,"given":"Jawad","family":"Khazaal","sequence":"additional","affiliation":[{"name":"College of Human Medicine, Michigan State University, Grand Rapids, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Human Medicine, Michigan State University, Grand Rapids, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-7656","authenticated-orcid":false,"given":"Jessica L","family":"Parker","sequence":"additional","affiliation":[{"name":"Office of Research and Education, Spectrum Health, Grand Rapids, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz A","family":"Timek","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Spectrum Health, Grand Rapids, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"2021052808395247000_ivab016-B1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jtcvs.2018.01.099","article-title":"A novel tissue treatment to reduce mineralization of bovine pericardial heart valves","volume":"156","author":"Meuris","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021052808395247000_ivab016-B2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.semtcvs.2017.08.003","article-title":"Aortic Valve Replacement: are We Spoiled for Choice?","volume":"29","author":"Bashir","year":"2017","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2021052808395247000_ivab016-B3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.athoracsur.2020.03.003","article-title":"The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2020 Update on Outcomes and Research","volume":"109","author":"Bowdish","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.athoracsur.2014.09.030","article-title":"Very long-term outcomes of the carpentier-edwards perimount valve in aortic position","volume":"99","author":"Bourguignon","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.athoracsur.2010.01.046","article-title":"Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients","volume":"89","author":"McClure","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-7120-9-37","article-title":"Early Doppler-echocardiography evaluation of Carpentier-Edwards Standard and Carpentier-Edwards Magna aortic prosthetic valve: comparison of hemodynamic performance","volume":"9","author":"Minardi","year":"2011","journal-title":"Cardiovasc Ultrasound"},{"key":"2021052808395247000_ivab016-B7","volume-title":"Commonly Utilized Equations in Echocardiography","author":"Ryding","year":"2013","edition":"2nd ed"},{"key":"2021052808395247000_ivab016-B8","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/eurheartj\/ehs255","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document","volume":"33","author":"Kappetein","year":"2012","journal-title":"Eur Heart J"},{"key":"2021052808395247000_ivab016-B9","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtcvs.2013.12.051","article-title":"Comparison of early hemodynamic performance of 3 aortic valve bioprostheses","volume":"148","author":"Ugur","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021052808395247000_ivab016-B10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/jocs.14212","article-title":"Hemodynamic performance and clinical outcome of pericardial Perimount Magna and Porcine Hancock-II valves in aortic position","volume":"34","author":"Caporali","year":"2019","journal-title":"J Card Surg"},{"key":"2021052808395247000_ivab016-B11","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1253\/circj.CJ-18-0744","article-title":"Trifecta vs. Magna for Aortic Valve Replacement - Differences in Clinical Outcome and Valve Hemodynamics","volume":"82","author":"Tadokoro","year":"2018","journal-title":"Circ J"},{"key":"2021052808395247000_ivab016-B12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.athoracsur.2018.10.063","article-title":"Trifecta Aortic Bioprosthesis: midterm Results in 1,953 Patients From a Single Center","volume":"107","author":"Kilic","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jocs.12726","article-title":"Long-Term Outcomes and Durability of the Mitroflow Aortic Bioprosthesis","volume":"31","author":"Mosquera","year":"2016","journal-title":"J Card Surg"},{"key":"2021052808395247000_ivab016-B14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.athoracsur.2017.09.053","article-title":"Long-Term Outcomes of the Mosaic Bioprosthesis","volume":"105","author":"Rie\u00df","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0038-1660517","article-title":"Hemodynamic results and mid-term follow-up of 850 19 to 23 mm perimount magna ease valves","volume":"67","author":"Anselmi","year":"2019","journal-title":"Thorac Cardiovasc Surg"},{"key":"2021052808395247000_ivab016-B16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ejcts\/ezv070","article-title":"The TRIBECA study: (TRI)fecta (B)ioprosthesis (E)valuation versus (C)arpentier Magna-Ease in (A)ortic position","volume":"49","author":"Colli","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021052808395247000_ivab016-B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.athoracsur.2019.12.071","article-title":"Trifecta versus Perimount Magna Ease Aortic Valve Prostheses","author":"Biancari","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/IMI.0000000000000534","article-title":"Magna Ease versus Trifecta Early Hemodynamics: a Systematic Review and Meta-analysis","volume":"13","author":"Yanagawa","year":"2018","journal-title":"Innovations(Phila)"},{"key":"2021052808395247000_ivab016-B19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.athoracsur.2011.01.051","article-title":"Industry-generated charts for the selection of stented aortic valve prostheses: clinical tool or marketing ploy?","volume":"91","author":"Cohen","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"2021052808395247000_ivab016-B20","first-page":"530","article-title":"How reliable is an effective orifice area indexed chart? - PubMed - NCBI","volume":"18","author":"House","year":"2009","journal-title":"J Hear Valve Dis"}],"container-title":["Interactive CardioVascular and Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/icvts\/article-pdf\/32\/6\/839\/38338124\/ivab016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/icvts\/article-pdf\/32\/6\/839\/38338124\/ivab016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T08:57:38Z","timestamp":1622192258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/icvts\/article\/32\/6\/839\/6133173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,11]]},"published-print":{"date-parts":[[2021,5,27]]}},"URL":"https:\/\/doi.org\/10.1093\/icvts\/ivab016","relation":{},"ISSN":["1569-9285"],"issn-type":[{"value":"1569-9285","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,2,11]]}}}